Cargando…

Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis

OBJECTIVE: To investigate the regulatory effect of tumour necrosis factor (TNF) blockade with infliximab on the distribution of peripheral blood monocyte subpopulations in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). METHODS: Purified CD11b+CD14+ monocytes from 5 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aeberli, Daniel, Kamgang, Richard, Balani, Deepak, Hofstetter, Willy, Villiger, Peter M, Seitz, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716562/ https://www.ncbi.nlm.nih.gov/pubmed/26819749 http://dx.doi.org/10.1136/rmdopen-2015-000079

Ejemplares similares

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
por: Barczyńska, Tacjana Anna, et al.
Publicado: (2015)

TNF-α Inhibitors Decrease Classical CD14(hi)CD16− Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis
por: Batko, Bogdan, et al.
Publicado: (2019)

Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

Serum Prolidase Activity in Ankylosing Spondylitis and Rheumatoid Arthritis
por: Uçar, Demet, et al.
Publicado: (2013)

Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2016)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
por: Schulz, Martin, et al.
Publicado: (2014)

Editorial The Role of Surgery in Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis
por: W.S, Khan, et al.
Publicado: (2015)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
por: Elalouf, Ofir, et al.
Publicado: (2015)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

Higher prevalence of peripheral arthritis among ankylosing spondylitis patients.
por: Lee, Ji-Hyun, et al.
Publicado: (2002)

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2018)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately
por: Khan, Nasim A, et al.
Publicado: (2021)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

Expression of VEGFA-mRNA in classical and MSX2-mRNA in non-classical monocytes in patients with spondyloarthritis is associated with peripheral arthritis
por: Stec, Małgorzata, et al.
Publicado: (2021)

Non-classical human leucocyte antigens in ankylosing spondylitis: possible association with HLA-E and HLA-F
por: Santos, Margarida Rodrigues, et al.
Publicado: (2018)

Transcriptomic characterization of classical monocytes highlights the involvement of immuno-inflammation in bone erosion in Rheumatoid Arthritis
por: Sales, Lucas Peixoto, et al.
Publicado: (2023)

Concurrence of Rheumatoid Arthritis and Ankylosing Spondylitis: Analysis of Seven Cases and Literature Review
por: Flores-Robles, Bryan-Josué, et al.
Publicado: (2022)

Non-classical monocytes as mediators of tissue destruction in arthritis
por: Puchner, Antonia, et al.
Publicado: (2018)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
por: Ferraro-Peyret, Carole, et al.
Publicado: (2004)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
por: Barbulescu, Andrei, et al.
Publicado: (2020)

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jeoij92qfph3028900roudksrm